If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
13 August 2020 Beijing-based BGI Genomics can continue to develop its DNA sequencing technology pending an appeal in a patent dispute with Illumina, a US federal court has ruled.
21 February 2020 Genetic sequencing company Illumina is seeking a preliminary injunction to stop its China-based rival BGI from distributing DNA sequencers in the US.
2 July 2019 Genetic sequencing company Illumina has continued its campaign of filing patent lawsuits against rival BGI, with the filing of three additional infringement suits.
13 August 2020 Beijing-based BGI Genomics can continue to develop its DNA sequencing technology pending an appeal in a patent dispute with Illumina, a US federal court has ruled.
21 February 2020 Genetic sequencing company Illumina is seeking a preliminary injunction to stop its China-based rival BGI from distributing DNA sequencers in the US.
2 July 2019 Genetic sequencing company Illumina has continued its campaign of filing patent lawsuits against rival BGI, with the filing of three additional infringement suits.
13 August 2020 Beijing-based BGI Genomics can continue to develop its DNA sequencing technology pending an appeal in a patent dispute with Illumina, a US federal court has ruled.
21 February 2020 Genetic sequencing company Illumina is seeking a preliminary injunction to stop its China-based rival BGI from distributing DNA sequencers in the US.
2 July 2019 Genetic sequencing company Illumina has continued its campaign of filing patent lawsuits against rival BGI, with the filing of three additional infringement suits.
